ERBB2 and breast cancer: Cyclin-dependent kinase (CDK) 4/6 inhibitors have been shown to be effective in the treatment of metastatic HR-positive BC and human epidermal growth factor receptor 2 (HER2)-negative BC combined with hormonal therapy (HT) [8].